60 Degrees Pharmaceuticals Files 8-K

TL;DR

60 Degrees Pharma inked a deal & sold equity, filing an 8-K on Feb 5th.

AI Summary

On February 5, 2025, 60 Degrees Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.

Why It Matters

This 8-K filing indicates significant corporate actions, including a material definitive agreement and equity sales, which could impact the company's financial structure and future operations.

Risk Assessment

Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.

Key Players & Entities

• 60 DEGREES PHARMACEUTICALS, INC. (company) — Registrant
• February 5, 2025 (date) — Date of earliest event reported
• 001-41719 (company) — SEC File Number
• 45-2406880 (company) — IRS Employer Identification Number

FAQ

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share SXTP The Nasdaq Stock Mar
• $0.715 — ("Common Stock") at a purchase price of $0.715 per share in a registered direct offeri
• $0.59 — of Common Stock at an exercise price of $0.59 per share. The Warrants are exercisable
• $15,000 — n-accountable expenses in the amount of $15,000 and a clearing fee in the amount of $10
• $10,000 — 000 and a clearing fee in the amount of $10,000. The Company also issued to the Placeme
• $0.8938 — arrants have an exercise price equal to $0.8938 per share and are exercisable upon issu
• $908,627.28 — received net proceeds of approximately $908,627.28 from the offering, after deducting esti

Filing Documents

• ea0230228-8k_60degrees.htm (8-K) — 45KB
• ea023022801ex4-1_60degrees.htm (EX-4.1) — 94KB
• ea023022801ex4-2_60degrees.htm (EX-4.2) — 92KB
• ea023022801ex5-1_60degrees.htm (EX-5.1) — 10KB
• ea023022801ex10-1_60degrees.htm (EX-10.1) — 247KB
• ea023022801ex99-1_60degrees.htm (EX-99.1) — 13KB
• ea023022801ex99-2_60degrees.htm (EX-99.2) — 14KB
• ex5-1_001.jpg (GRAPHIC) — 8KB
• 0001213900-25-010962.txt ( ) — 873KB
• sxtp-20250205.xsd (EX-101.SCH) — 4KB
• sxtp-20250205_def.xml (EX-101.DEF) — 26KB
• sxtp-20250205_lab.xml (EX-101.LAB) — 36KB
• sxtp-20250205_pre.xml (EX-101.PRE) — 25KB
• ea0230228-8k_60degrees_htm.xml (XML) — 6KB

01 Entry into a Material Definitive

Item 1.01 Entry into a Material Definitive Agreement. On February 5, 2025, 60 Degrees Pharmaceuticals, Inc., a Delaware corporation (the "Company"), entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain institutional investors (the "Purchasers") pursuant to which the Company sold, in a registered direct offering an aggregate of 1,503,500 shares (the "Shares") of common stock, par value $0.0001 per share, of the Company ("Common Stock") at a purchase price of $0.715 per share in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market LLC. The Shares were offered pursuant to a "shelf" registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the Securities and Exchange Commission (the "SEC") on July 18, 2024 as supplemented by a prospectus supplement dated February 5, 2025, filed with the SEC on February 6, 2025, and accompanying base prospectus, pursuant to Rule 424(b)(5) promulgated under the Securities Act of 1933, as amended (the "Securities Act"). In a concurrent private placement, the Company also issued to the Purchasers unregistered warrants (the "Warrants") to purchase up to an aggregate of 1,503,500 shares (the "Warrant Shares") of Common Stock at an exercise price of $0.59 per share. The Warrants are exercisable upon issuance and expire twenty-four months from the date of issuance. Pursuant to the Securities Purchase Agreement, the Company is required to file a registration statement with the SEC within 45 days after the date of the Securities Purchase Agreement to register the Warrant Shares under the Securities Act. The Company shall use commercially reasonable efforts to cause such registration statement to become effective within 75 days following the Closing Date and to keep such registration statement effective at all times until no Purchaser owns any Warrants or Warrant Shares issuable upon exercise thereof. Any holder will not

02. Unregistered Sales of Equity Securities

Item 3.02. Unregistered Sales of Equity Securities. The disclosures set forth in Item 1.01 of this Current Report on Form 8-K (this "Report") with respect to the Warrants and the Placement Agent Warrants (and the shares of Common Stock issuable hereunder) are hereby incorporated by reference into this Item 3.02.

01. Other Events

Item 8.01. Other Events. On February 5, 2025, the Company issued a press release announcing the pricing of the offering. A copy of the press release announcing this matter is filed as Exhibit 99.1 to this Report and is incorporated by reference into this Item 8.01. On February 6, 2025, the Company issued a press release announcing the closing of the offering. A copy of the press release announcing this matter is filed as Exhibit 99.2 to this Report and is incorporated by reference into this Item 8.01.

01. Exhibits

Item 9.01. Exhibits. (d) Exhibits Exhibit No. Description 1.1 Engagement Agreement (incorporated by reference to Exhibit 1.1 of the Company's Current Report on Form 8-K filed on January 30, 2025) 1.2 Amendment to Engagement Agreement (incorporated by reference to Exhibit 1.2 of the Company's Current Report on Form 8-K filed on January 30, 2025) 1.3 Extension to Engagement Agreement (incorporated by reference to Exhibit 1.3 of the Company's Current Report on Form 8-K filed on January 30, 2025) 4.1 Form of Warrant 4.2 Form of Placement Agent Warrant 5.1 Opinion of Sichenzia Ross Ference Carmel LLP 10.1 Form of Securities Purchase Agreement 23.1 Consent of Sichenzia Ross Ference Carmel LLP (contained in Exhibit 5.1) 99.1 Press Release, dated February 5, 2025 99.2 Press Release, dated February 6, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. 60 DEGREES PHARMACEUTICALS, INC. Date: February 6, 2025 By: /s/ Geoffrey Dow Name: Geoffrey Dow Title: Chief Executive Officer and President 3

View Full Filing

View this 8-K filing on SEC EDGAR